Todd S. Crocenzi

Todd S. Crocenzi

Auto-generated profile, based on publicly available information

Todd S. Crocenzi

Providence Cancer Center at Providence Health & Services, Portland, OR 97213, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2017 in Science
Verified
Journal Article
Closed access
PDF file
DLDung T. Le
Dung T. Le
JDJennifer N. Durham
Jennifer N. Durham
KSKellie N. Smith
Kellie N. Smith
HWHao Wang
Hao Wang
BBBjarne R. Bartlett
Bjarne R. Bartlett
LDLuis A. Diaz
Luis A. Diaz
Predicting responses to immunotherapy: Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinical trial, Le et al. showed that treatment success is not just limited to colon cancer (see the Perspective by Goswami and Sharma). They found that a wide range of different cancer types with MMR deficiency also responded to PD-1 blockade. The trial included some patients with pancreatic cancer, which is one of the deadliest forms of cancer. The clinical trial is still ongoing, and around 20% of patients have so far achieved a complete response. MMR deficiency appears to be a biomarker for predicting successful treatment outcomes for several solid tumors and indicates a new therapeutic option for patients harboring MMR-deficient cancers. Science , this issue p. 409 ; see also p. 358

26 June 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
IMIGNACIO MELERO
IGNACIO MELERO
AEAnthony El-Khoueiry
Anthony El-Khoueiry
TYThomas Yau
Thomas Yau
CHChih-Hung Hsu
Chih-Hung Hsu
Masatoshi KudoMasatoshi Kudo
Masatoshi Kudo
TMTim Meyer
Tim Meyer
Introduction: Patients with hepatocellular carcinoma (HCC) are often diagnosed at an advanced age and a large majority progress on current standard-of-care sorafenib therapy. The clinical benefit of systemic therapies in patients with HCC who are of advanced age is not well studied, although some prior reports suggest that efficacy and safety of sorafenib are not significantly affected by patient age (Di Costanzo et al, Med Oncol 2013). Here we report efficacy and safety of the programmed death-1 (PD-1) inhibitor nivolumab in age groups of patients with advanced HCC in the CheckMate 040 study (NCT01658878).

20 January 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DLDung T. Le
Dung T. Le
AWAndrea Wang-Gillam
Andrea Wang-Gillam
VPVincent J. Picozzi
Vincent J. Picozzi
TCTodd S. Crocenzi
Todd S. Crocenzi
MMMichael Morse
Michael Morse
EJElizabeth M. Jaffee
Elizabeth M. Jaffee
TPS489 Background: A prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing activity in patients with metastatic pancreatic adenocarcinoma (PDA). GVAX is composed of lethally-irradiated, allogeneic pancreatic cancer cells modified to express GM-CSF. GVAX induces a response against multiple tumor antigens and is given after low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and stimulates both innate and adaptive immunity by activating T cells and NK cells. Results from a phase 2 study demonstrated CY/GVAX plus CRS-207 improved overall survival (OS) compared to CY/GVAX alone (p-value<0.05; Le, GI ASCO 2014). Methods: This is a phase 2b study comparing CY/GVAX and CRS-207 to chemotherapy or to CRS-207 alone in patients with previously-treated metastatic PDA. Patients will be enrolled in two cohorts: 150 patients into a primary cohort of patients with at least two prior chemotherapy regimens for metastatic disease (third + line) and 90 patients into an exploratory cohort of patients with only one prior chemotherapy regimen for metastatic disease (second line). Patients will be randomized in a 1:1:1 ratio to receive 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm A), six doses of CRS-207 (Arm B) or physician’s choice of single-agent chemotherapy (Arm C). The primary objective is to compare OS between Arms A and C in the primary cohort. Secondary/exploratory objectives include: comparison of OS in both primary and exploratory cohorts between all treatment arms, assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of Lm- and mesothelin-specific T cell and other immunological responses with clinical responses. Updated enrollment will be reported. (Sponsor: Aduro BioTech, Inc.; NCT02004262). Clinical trial information: NCT02004262.

20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKS. L. Ketchum
S. L. Ketchum
BCB. Cole
B. Cole
KMKim allyson Margolin
Kim allyson Margolin
DMD. McDermott
D. McDermott
TCT. Crocenzi
T. Crocenzi
MEMarc S Ernstoff
Marc S Ernstoff
8034 Background: Lymphocyte depletion followed by homeostatic recovery has been shown to break tumor-specific tolerance. We have initiated a clinical trial of chemotherapy-induced lymphodepletion followed by high-dose (HD) IL-2 + GM-CSF in metastatic melanoma (MM) patients (pts). Methods: Pts with PS 0–1, normal organ function and with measurable MM were treated with intravenous cyclophosphamide 60 mg/kg (day 1–2), fludarabine 25 mg/m2 (day 3–7) followed by two 5-day (d) courses of intravenous HD bolus IL-2 600,000 IU/kg (d 8–12 and 21–25) and daily subcutaneous administration of GM-CSF 250 mcg/m2 (d 8 until granulocyte recovery). Results: 8 pts are presently evaluable in this first stage of accrual to confirm safety and immunomodulation. A mean of 25/28 IL-2 doses were delivered. All pts experienced transient myelosuppression with ANC < 500 cells/mm3 for a median of 7d (range 5–11d) and platelets <50,000/mm3 for a median of 5.5 days (range 0–7d). Pts exhibited reversible capillary leak associated with high-dose IL-2. With the exception of myelosuppression, no grade 4 toxicities occurred. All pts experienced neutropenic fever and 2 developed line infections. CD4+/CD25high/CD62L+ T cells rebounded by d 14, peaked around d 28 and returned to baseline by d 85. CD8+/CD28- T cells recovered to levels lower than baseline for the first 28d but then showed persistent elevation through d 113. Skewing of T-cell populations based on TCR β chain expression was observed. One pt achieved complete response, 2 achieved partial responses, and 5 progressed. Conclusions: Lymphodepletion followed by high-dose IL-2 can be safely administered, affects immune reconstitution, and has activity in MM that may be useful as a platform for enhancing immunotherapeutic strategies. The trial continues to accrue in order to better estimate antitumor activity and immunomodulation. No significant financial relationships to disclose.